Identification of 6-substituted 4-arylsulfonyl-1,4-diazepane-2,5-diones as a novel scaffold for human chymase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 12, 2007, Pages 3431-3434

  Tanaka, Taisaku ^a   Muto, Tsuyoshi ^a   Maruoka, Hiroshi ^a   Imajo, Seiichi ^a   Fukami, Harukazu ^b   Tomimori, Yoshiaki ^a   Fukuda, Yoshiaki ^a   Nakatsuka, Takashi ^a  

^a DAIICHI SANKYO CO   (Japan)

^b Faculty of Bioenvironmental Science   (Japan)

Author keywords

4 Arylsulfonyl 1,4 diazepane 2,5 dione; Chymase; Inhibitor

Indexed keywords

CHYMASE; CHYMASE INHIBITOR; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; SULFONE DERIVATIVE;

ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

AZEPINES; CHYMASES; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34249292982     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.03.038     Document Type: Article

References (30)

1. Urata H., Kinoshita A., Misono K.S., Bumpus F.M., and Husain A. J. Biol. Chem. 265 (1990) 22348
2. Nakano A., Kishi F., Minami K., Wakabayashi H., Nakaya Y., and Kido H. J. Immunol. 159 (1997) 1987
3. Kovanen P.T. Heart Vessels Suppl. 12 (1997) 125 and references therein
4. Uehara Y., Urata H., Ideshima M., Arakawa K., and Saku K. Cardiovasc. Res. 55 (2002) 870
5. Takai S., Sakonjo H., Fukuda K., Jin D., Sakaguchi M., Kamoshita K., Ishida K., Sukenaga Y., and Miyazaki M. J. Pharmacol. Exp. Ther. 304 (2003) 841
6. Matsumoto T., Wada A., Tsutamoto T., Ohnishi M., Isono T., and Kinoshita M. Circulation 107 (2003) 2522
7. Kofford M.W., Schwartz L.B., Schechter N.M., Yager D.R., Diegelmann R.F., and Graham M.F. J. Biol. Chem. 272 (1997) 7127
8. Saarinen J., Kalkkinen N., Welgus H.G., and Kovanen P.T. J. Biol. Chem. 269 (1994) 18134
9. Tchouqounova E., Lundequist A., Winberg J.O., Abrink M., and Pejler G. J. Biol. Chem. 280 (2005) 9291
10. Mizutani H., Schechter N., Lazarus G., Black R.A., and Kupper T.S. J. Exp. Med. 174 (1991) 821
11. Taipale J., Lohi J., Saarinen J., Kovanen P.T., and Keski-Oja J. J. Biol. Chem. 270 (1995) 4689
12. Tomimori Y., Muto T., Saito K., Tanaka T., Maruoka H., Sumida M., Fukami H., and Fukuda Y. Eur. J. Pharmacol. 478 (2003) 179
13. Longley B.J., Tyrrell L., Ma Y., Willams D.A., Halaban R., Langley K., Lu H.S., and Schechter N.M. Proc. Natl Acad. Sci. U.S.A. 94 (1997) 9017;
14. Tomimori Y., Muto T., Fukami H., Saito K., Horikawa C., Tsuruoka N., Yamashiro K., Saito M., Sugiura N., Sumida M., Kakutani S., and Fukuda Y. Biochem. Biophys. Res. Commun. 290 (2002) 1478
15. Tomimori Y., Muto T., Fukami H., Saito K., Horikawa C., Tsuruoka N., Saito M., Sugiura N., Yamashiro K., Sumida M., Kakutani S., and Fukuda Y. Lab. Invest. 82 (2002) 789
16. Watanabe N., Tomimori Y., Saito K., Miura K., Wada A., Tsudzuki M., and Fukuda Y. Int. Arch. Allergy Immunol. 128 (2002) 229
17. Kanemitsu H., Takai S., Tsuneyoshi H., Nishina T., Yoshikawa K., Miyazaki M., Ikeda T., and Komeda M. Hypertens. Res. 29 (2006) 57
18. Tomimori Y., Muto T., Saito K., Tanaka T., Maruoka H., Sumida M., Fukami H., and Fukuda Y. Eur. J. Pharmacol. 478 (2003) 179
19. Sakaguchi M., Takai S., Jin D., Okamoto Y., Muramatsu M., Kim S., and Miyazaki M. Eur. J. Pharmacol. 493 (2004) 173
20. Takai S., Jin D., Muramatsu M., Okamoto Y., and Miyazaki M. Eur. J. Pharmacol. 501 (2004) 1
21. Muto T., and Fukami H. IDrugs 5 (2002) 1141
22. Fukami H., Imajo S., Ito A., Kakutani S., Shibata S., Sumida M., Tanaka T., Niwata S., Saitoh M., Kiso Y., Miyazaki M., Okunishi H., Urata H., and Arakawa K. Drug Des. Discov. 17 (2000) 69
23. Compounds 6o and 6p for the synthesis of 2o and 2p were synthesized from 6m via intermediate 15 by a five-step sequence of reactions, as shown below.{A figure is presented}.
24. 2) was needed to remove the methoxymethyl group which protected the phenolic hydroxy group during the reaction sequence.
25. Takeuchi, Y. Jpn. Kokai Tokkyo Koho, JP 2004300036.
26. Ojima I., and Yoda N. Tetrahedron Lett. 21 (1980) 1051
27. Jendralla H. Tetrahedron Lett. 32 (1991) 3671
28. The expression and purification of recombinant human chymase are described in Ref. 11b.
29. 50 value was calculated from the inhibition of AMC formation at each concentration of the tested compound.
30. 2 for trypsin.